The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Hepatitis C and Progression of HIV Disease
Abstract
CONTEXT: Conflicting reports exist regarding the effect of hepatitis C virus (HCV) on the progression of human immunodeficiency virus (HIV) disease. OBJECTIVE: To assess the effect of HCV infection on clinical and immunologic progression of HIV disease and immunologic response to highly active antiretroviral therapy (HAART). DESIGN: Prospective cohort study. SETTING: University-based, urban HIV clinic in the United States. PATIENTS: There were 1955 patients enrolled between January 1995 and January 2001 who were eligible for analysis because of having at least 1 return visit to the clinic and being free of acquired immunodeficiency syndrome (AIDS) at enrollment. Median (interquartile range) length of follow-up was 2.19 (1.00-3.50) years for HCV-infected and 2.00 (1.00-3.00) years for HCV-uninfected patients. MAIN OUTCOME MEASURES: Progression to an AIDS-defining illness, survival, and progression to a CD4 cell count below 200/microL; CD4 cell count change following initiation of effective HAART (resulting in a viral load of <400 copies/mL recorded at > or = 75% of measurements). RESULTS: No difference was detected in the risk of acquiring an AIDS-defining illness (HCV-infected patients, 231 events [26.4%] and HCV-uninfected patients, 264 events [24.4%]; relative hazard [RH], 1.03; 95% confidence interval [CI], 0.86-1.23) or in the risk of death (HCV-infected patients, 153 deaths [17.5%] and HCV-uninfected patients, 168 deaths [15.5%]; RH, 1.05; 95% CI, 0.85 -1.30). Although an increased risk of death was detected in the subgroup of 429 HCV-infected patients with a baseline CD4 cell count of 50/microL through 200/microL (RH, 1.51; 95% CI, 1.01-2.27), after adjustment for exposure to HAART and its effectiveness in a multivariate Cox regression analysis, death was not independently associated with HCV infection in this subgroup (RH, 1.01; 95% CI, 0.65-1.56). Similarly, in those receiving effective HAART (n = 208), there was no difference in the increase in CD4 cell count or CD4 percentage during HAART in HCV-infected compared with HCV-uninfected patients. CONCLUSIONS: Among patients in this urban US cohort, we did not detect evidence that HCV infection substantially alters the risk of dying, developing AIDS, or responding immunologically to HAART, especially after accounting for differences in its administration and effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Castro, K. G., Ward, J. W., Slutsker, L., Buehler, J. W., Jaffe, H. W., Berkelman, R. L., & Curran, J. W. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.802 · Cited by 4,349
Zhang, J., & Yu, K. F. (1998) · JAMA · doi:10.1001/jama.280.19.1690 · Cited by 4,138
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,992
The Natural History of Hepatitis C Virus Infection: Host, Viral, and Environmental Factors
Thomas, D. L., Astemborski, J., Rai, R. M., Anania, F. A., Schaeffer, M., Galai, N., Nolt, K., Nelson, K. E., Strathdee, S. A., Johnson, L., et al. (2000) · JAMA · doi:10.1001/jama.284.4.450 · Cited by 1,073
Sulkowski, M. S. (2000) · JAMA · doi:10.1001/jama.283.1.74 · Cited by 950
Self-citationImproved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy
Hogg, R. S. (1998) · JAMA · doi:10.1001/jama.279.6.450 · Cited by 850
Detels, R. (1998) · JAMA · doi:10.1001/jama.280.17.1497 · Cited by 739
(1997) · Hepatology · doi:10.1002/hep.510260701 · Cited by 569
Barriers to Use of Free Antiretroviral Therapy in Injection Drug Users
Strathdee, S. A. (1998) · JAMA · doi:10.1001/jama.280.6.547 · Cited by 505
Darby, S. C., Ewart, D. W., Giangrande, P. L., Spooner, R. J., Rizza, C. R., Dusheiko, G. M., Lee, C. A., Ludlam, C. A., & Preston, F. E. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05413-5 · Cited by 497
Infection with GB Virus C and Reduced Mortality among HIV-Infected Patients
Tillmann, H. L., Heiken, H., Knapik-Botor, A., Heringlake, S., Ockenga, J., Wilber, J. C., Goergen, B., Detmer, J., McMorrow, M., Stoll, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010398 · Cited by 399
den Brinker, M., Wit, F. W. N. M., Wertheim-van Dillen, P. M. E., Jurriaans, S., Weel, J., van Leeuwen, R., Pakker, N. G., Reiss, P., Danner, S. A., Jan Weverling, G., et al. (2000) · AIDS · doi:10.1097/00002030-200012220-00011 · Cited by 390
Effect of Coinfection with GB Virus C on Survival among Patients with HIV Infection
Xiang, J., Wünschmann, S., Diekema, D. J., Klinzman, D., Patrick, K. D., George, S. L., & Stapleton, J. T. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003364 · Cited by 379
Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community
Moore, R. D., Stanton, D., Gopalan, R., & Chaisson, R. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403173301107 · Cited by 356
Detrimental Effects of Continued Illicit Drug Use on the Treatment of HIV-1 Infection
Lucas, G. M., Cheever, L. W., Chaisson, R. E., & Moore, R. D. (2001) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200107010-00006 · Cited by 350
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
Martínez, E., Blanco, J. L., Arnaiz, J. A., Pérez-Cuevas, J. B., Mocroft, A., Cruceta, A., Marcos, M. A., Milinkovic, A., García-Viejo, M. A., Mallolas, J., et al. (2001) · AIDS · doi:10.1097/00002030-200107060-00007 · Cited by 349
Problems With Proper Completion and Accuracy of the Cause-of-Death Statement
Sehdev, A. E. S., & Hutchins, G. M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.2.277 · Cited by 342
Monga, H. K., Rodriguez‐Barradas, M. C., Breaux, K., Khattak, K., Troisi, C. L., Velez, M., & Yoffe, B. (2001) · Clinical Infectious Diseases · doi:10.1086/321819 · Cited by 321
Self-reported Antiretroviral Therapy in Injection Drug Users
Celentano, D. D. (1998) · JAMA · doi:10.1001/jama.280.6.544 · Cited by 258
Sulkowski, M. S., Mast, E. E., Seeff, L. B., & Thomas, D. L. (2000) · Clinical Infectious Diseases · doi:10.1086/313842 · Cited by 251
Self-citationLesens, O., Deschênes, M., Steben, M., Bélanger, G., & Tsoukas, C. M. (1999) · The Journal of Infectious Diseases · doi:10.1086/314720 · Cited by 218
Piroth, L., Duong, M., Quantin, C., Abrahamowicz, M., Michardiere, R., Aho, L.-S., Grappin, M., Buisson, M., Waldner, A., Portier, H., et al. (1998) · AIDS · doi:10.1097/00002030-199804000-00006 · Cited by 191
Coinfection of Hepatitis C Virus with Human Immunodeficiency Virus and Progression to AIDS
Dorrucci, M., Pezzotti, P., Phillips, A. N., Cozzi‐Lepri, A., Rezza, G., & Study, I. S. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/172.6.1503 · Cited by 153
Screening for Hepatitis C Virus in Human Immunodeficiency Virus-Infected Individuals
Thio, C. L., Nolt, K. R., Astemborski, J. A., Vlahov, D., Nelson, K. E., & Thomas, D. L. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.2.575-577.2000 · Cited by 141
Broers, B., Junet, C., Bourquin, M., Déglon, J., Perrin, L. H., & Hirschel, B. J. (1998) · AIDS · doi:10.1097/00002030-199815000-00018 · Cited by 121
Determinants of the Quantity of Hepatitis C Virus RNA
Thomas, D. L., Astemborski, J. A., Vlahov, D., Strathdee, S. A., Ray, S. C., Nelson, K. E., Galai, N., Nolt, K. R., Laeyendecker, O. B., & Todd, J. A. (2000) · The Journal of Infectious Diseases · doi:10.1086/315314 · Cited by 111
Christensen, J. K., Eugen‐Olsen, J., Sørensen, M., Ullum, H., Gjedde, S. B., Pedersen, B. K., Nielsen, J. O., & Krogsgaard, K. (2000) · The Journal of Infectious Diseases · doi:10.1086/315440 · Cited by 98
Lok, A. S.-F., & Gunaratnam, N. T. (1997) · Hepatology · doi:10.1002/hep.510260709 · Cited by 82
Pre-AIDS mortality from natural causes associated with HIV disease progression
Prins, M., Hernández‐Aguado, I., Brettle, R. P., Robertson, R., Broers, B., Carré, N., Goldberg, D. J., Zangerle, R., Coutinho, R. A., & van den Hoek, A. (1997) · AIDS · doi:10.1097/00002030-199714000-00012 · Cited by 62
Haydon, G. H., Flegg, P. J., Blair, C. S., Brettle, R. P., Burns, S. M., & Hayes, P. C. (1998) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199806000-00009 · Cited by 55
Goedert, J. J., Fung, M. S. C., Felton, S., Battjes, R. J., & Engels, E. A. (2001) · AIDS · doi:10.1097/00002030-200107060-00012 · Cited by 54
Cited by
Global epidemiology of hepatitis C virus infection
Shepard, C. W., Finelli, L., & Alter, M. J. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70216-4 · Cited by 2,758
Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus: The D:A:D Study
(2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1632 · Cited by 1,113
Redefining Chronic Viral Infection
Virgin, H. W., Wherry, E. J., & Ahmed, R. (2009) · Cell · doi:10.1016/j.cell.2009.06.036 · Cited by 1,031
Qurishi, N., Kreuzberg, C., Lüchters, G., Effenberger, W., Kupfer, B., Sauerbruch, T., Rockstroh, J. K., & Spengler, U. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14844-1 · Cited by 525
Hepatitis C in the HIV-Infected Person
Sulkowski, M. S., & Thomas, D. L. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-3-200302040-00012 · Cited by 405
Self-citation
Metadata
- Authors
- Sulkowski, M. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2002-07-10
- Volume
- 288
- Issue
- 2
- Pages
- 199
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2074115135
- Cited by
- 445
- References
- 32
- FWCI
- 28.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.